Cyclin-dependent kinase 1-mediated phosphorylation of SET at serine 7 is essential for its oncogenic activity

[1]  Ana C. Henriques,et al.  Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution. , 2019, Cancer letters.

[2]  S. Lele,et al.  Zyxin promotes colon cancer tumorigenesis in a mitotic phosphorylation-dependent manner and through CDK8-mediated YAP activation , 2018, Proceedings of the National Academy of Sciences.

[3]  Kuen-Feng Chen,et al.  Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[4]  K. Ye,et al.  CK2 Phosphorylating I2PP2A/SET Mediates Tau Pathology and Cognitive Impairment , 2018, Front. Mol. Neurosci..

[5]  K. Ye,et al.  CK2 Phosphorylating I2PP2A/SET Mediates Tau Pathology and Cognitive Impairment , 2018, Frontiers in Molecular Neuroscience.

[6]  Jiuli Zhou,et al.  CDK1-mediated mitotic phosphorylation of PBK is involved in cytokinesis and inhibits its oncogenic activity. , 2017, Cellular signalling.

[7]  D. Reinberg,et al.  Phospho-H1 Decorates the Inter-chromatid Axis and Is Evicted along with Shugoshin by SET during Mitosis. , 2017, Molecular cell.

[8]  Xiaoyong Li,et al.  Regulation of SET Gene Expression by NFkB , 2016, Molecular Neurobiology.

[9]  Shi-Wen Jiang,et al.  Oncogenic Role of SET/I2PP2A for Gynecologic Cancers. , 2017, Current drug targets.

[10]  H. Mody,et al.  SET contributes to the epithelial-mesenchymal transition of pancreatic cancer , 2017, Oncotarget.

[11]  Kuen-Feng Chen,et al.  Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer , 2017, Expert opinion on therapeutic targets.

[12]  C. Shiau,et al.  Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential , 2016, Oncogene.

[13]  Yuanhong Chen,et al.  Ajuba Phosphorylation by CDK1 Promotes Cell Proliferation and Tumorigenesis* , 2016, The Journal of Biological Chemistry.

[14]  T. Mak,et al.  Targeting Mitosis in Cancer: Emerging Strategies. , 2015, Molecular cell.

[15]  Kuen-Feng Chen,et al.  SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A , 2015, Oncotarget.

[16]  M. Gleave,et al.  Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis , 2015, Scientific Reports.

[17]  Nicholas Y. Palermo,et al.  The Hippo Pathway Effector YAP Regulates Motility, Invasion, and Castration-Resistant Growth of Prostate Cancer Cells , 2015, Molecular and Cellular Biology.

[18]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[19]  F. Rojo,et al.  Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer , 2014, Clinical Cancer Research.

[20]  Colin J. Daniel,et al.  Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer , 2014, Proceedings of the National Academy of Sciences.

[21]  R. Sears,et al.  Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia , 2014, Clinical Cancer Research.

[22]  Miao Liu,et al.  CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation. , 2013, Cancer research.

[23]  M. Caligiuri,et al.  PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. , 2013, The Journal of clinical investigation.

[24]  M. Caligiuri,et al.  Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. , 2013, Blood.

[25]  Jian-Zhi Wang,et al.  Ser9 phosphorylation causes cytoplasmic detention of I2 PP2A/SET in Alzheimer disease , 2013, Neurobiology of Aging.

[26]  Zhenbo Wang,et al.  Overexpression of SET&bgr;, a protein localizing to centromeres, causes precocious separation of chromatids during the first meiosis of mouse oocytes , 2013, Journal of Cell Science.

[27]  M. Ji,et al.  KIBRA Regulates Aurora Kinase Activity and Is Required for Precise Chromosome Alignment During Mitosis* , 2012, The Journal of Biological Chemistry.

[28]  M. Malumbres,et al.  Killing cells by targeting mitosis , 2012, Cell Death and Differentiation.

[29]  M. Vitek,et al.  SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. , 2011, Blood.

[30]  R. Medema,et al.  Mitosis as an anti-cancer target , 2011, Oncogene.

[31]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[32]  M. Ji,et al.  KIBRA Regulates Hippo Signaling Activity via Interactions with Large Tumor Suppressor Kinases* , 2011, The Journal of Biological Chemistry.

[33]  D. Wink,et al.  Targeting SET/I2PP2A Oncoprotein Functions as a Multi-pathway Strategy for Cancer Therapy , 2010, Oncogene.

[34]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[35]  S. Brunak,et al.  Quantitative Phosphoproteomics Reveals Widespread Full Phosphorylation Site Occupancy During Mitosis , 2010, Science Signaling.

[36]  D. Cleveland,et al.  Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis , 2009, Nature Reviews Molecular Cell Biology.

[37]  S. Elledge,et al.  A quantitative atlas of mitotic phosphorylation , 2008, Proceedings of the National Academy of Sciences.

[38]  G. Feldmann,et al.  Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.

[39]  M. Mumby.  PP2A: Unveiling a Reluctant Tumor Suppressor , 2007, Cell.

[40]  O. Bachs,et al.  Proteomic analysis of SET‐binding proteins , 2007, Proteomics.

[41]  Tohru Natsume,et al.  Shugoshin collaborates with protein phosphatase 2A to protect cohesin , 2006, Nature.

[42]  Guido Marcucci,et al.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. , 2005, Cancer cell.

[43]  M. Hollingsworth,et al.  Notch2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells , 2005, Laboratory Investigation.

[44]  G. Grosveld,et al.  Effects of SET and SET-CAN on the differentiation of the human promonocytic cell line U937 , 2004, Leukemia.

[45]  O. Bachs,et al.  The SET Protein Regulates G2/M Transition by Modulating Cyclin B-Cyclin-dependent Kinase 1 Activity* , 2003, The Journal of Biological Chemistry.

[46]  P. McNamara,et al.  Regulation of Histone Acetylation and Transcription by INHAT, a Human Cellular Complex Containing the Set Oncoprotein , 2001, Cell.

[47]  O. Bachs,et al.  The Protein SET Regulates the Inhibitory Effect of p21Cip1 on Cyclin E-Cyclin-dependent Kinase 2 Activity* , 1999, The Journal of Biological Chemistry.

[48]  K. Nagata,et al.  Cellular localization and expression of template-activating factor I in different cell types. , 1998, Experimental cell research.

[49]  Z. Damuni,et al.  The Myeloid Leukemia-associated Protein SET Is a Potent Inhibitor of Protein Phosphatase 2A (*) , 1996, The Journal of Biological Chemistry.

[50]  A. Murray,et al.  Members of the NAP/SET family of proteins interact specifically with B- type cyclins , 1995, The Journal of cell biology.

[51]  Hong Guo,et al.  Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. , 1995, Biochemistry.

[52]  T. Copeland,et al.  Identification of in vivo phosphorylation sites of SET, a nuclear phosphoprotein encoded by the translocation breakpoint in acute undifferentiated leukemia , 1994, FEBS letters.

[53]  Erich A. Nigg,et al.  Cellular substrates of p34cdc2 and its companion cyclin-dependent kinases , 1993 .

[54]  Marieke,et al.  Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene , 1992, Molecular and cellular biology.

[55]  G. Narla,et al.  Therapeutic targeting of PP2A. , 2018, The international journal of biochemistry & cell biology.

[56]  G. Collins.  The next generation. , 2006, Scientific American.

[57]  Z. Damuni,et al.  I1PP2A and I2PP2A. Two potent protein phosphatase 2A-specific inhibitor proteins. , 1998, Methods in molecular biology.

[58]  E. Nigg,et al.  Cellular substrates of p34(cdc2) and its companion cyclin-dependent kinases. , 1993, Trends in cell biology.